Overview

Efficacy and Safety of Teicoplanin in CDAD

Status:
Terminated

Trial end date:
2021-03-10

Target enrollment:

Participant gender:

Summary

Primary Objective: Explore the efficacy of teicoplanin (100-200 mg administered orally twice a day for 7 to 14 days) in patients with Clostridium difficile infection-associated diarrhea and colitis Secondary Objective: Evaluate the safety of teicoplanin in patients with Clostridium difficile infection-associated diarrhea and colitis

Phase:

Phase 4

Details

Lead Sponsor:

Sanofi

Treatments:

Teicoplanin